Skip to main content
. Author manuscript; available in PMC: 2021 May 13.
Published in final edited form as: Nano Lett. 2020 May 4;20(5):4051–4058. doi: 10.1021/acs.nanolett.0c01654

Figure 4.

Figure 4.

Synthesis and characterization of MΦ-MOF-uricase. (a) Diameter of MΦ-MOF, MOF-uricase, MΦ-MOF-uricase, and MΦ membrane vesicles after fabrication (n = 3, mean + SD). (b) Zeta potential of MΦ-MOF, MOF-uricase, MΦ-MOF-uricase, and MΦ membrane vesicles after fabrication (n = 3, mean + SD). (c) In vitro uric acid conversion by MΦ-MOF or MΦ-MOF-uricase normalized to free uricase activity (n = 3, mean + SD). (d) Western blot for cytokine receptors, including IL1R1 (80 kDa), IL1R2 (45 kDa), TNFR1 (55 kDa), TNFR2 (75 kDa), IL6Rα (80 kDa), and gp130 (130 kDa), on RBC membrane, MΦ membrane, RBC-MOF-uricase, and MΦ-MOF-uricase. (e-g) In vitro neutralization of cytokines, including IL1β (e), TNFα (f), and IL6 (g), by RBC-MOF-uricase and MΦ-MOF-uricase at various nanoparticle concentrations (n = 3, mean ± SD; four-parameter logistic regression).